True Wealth Design LLC Acquires 424 Shares of Johnson & Johnson (NYSE:JNJ)

True Wealth Design LLC grew its holdings in Johnson & Johnson (NYSE:JNJ) by 52.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,225 shares of the company’s stock after acquiring an additional 424 shares during the period. True Wealth Design LLC’s holdings in Johnson & Johnson were worth $177,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in JNJ. IFS Advisors LLC grew its stake in Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after acquiring an additional 100 shares in the last quarter. WealthTrak Capital Management LLC purchased a new position in Johnson & Johnson during the fourth quarter valued at $26,000. Mountain Hill Investment Partners Corp. purchased a new position in shares of Johnson & Johnson in the 4th quarter worth $29,000. Bay Harbor Wealth Management LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter worth $32,000. Finally, Conquis Financial LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter worth $33,000. 69.55% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on JNJ shares. Leerink Partners cut shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Stifel Nicolaus dropped their price target on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research note on Thursday, January 23rd. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Finally, StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Eleven equities research analysts have rated the stock with a hold rating, seven have given a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus target price of $170.88.

Insider Activity at Johnson & Johnson

In related news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares of the company’s stock, valued at $3,483,645.88. The trade was a 25.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at $2,357,552.70. The trade was a 2.60% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 1.2%

Shares of NYSE JNJ opened at $151.37 on Friday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The firm’s 50 day moving average price is $156.27 and its 200 day moving average price is $153.90. The firm has a market cap of $364.20 billion, a P/E ratio of 22.76, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating analysts’ consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be issued a dividend of $1.30 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. This represents a $5.20 annualized dividend and a dividend yield of 3.44%. Johnson & Johnson’s payout ratio is presently 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.